Drug
GSK573719 clinical trials
Also written GSK573719 and Umeclidinium.
Keep track of what changes. Save the GSK573719 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
51 studies that test it; most in 2011 (7)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 43 · Other 8
GlaxoSmithKline (40) · Novartis Pharmaceuticals (2) · Dr. Grace Parraga (1) · Luis Puente Maestu (1) · Thammasat University (1) · Stiefel, a GSK Company (1) · Queen's University (1) · University of Tennessee Graduate School of Medicine (1)
Often tested with
Tested in the same studies.
Vilanterol (25) · Fluticasone furoate (18) · Glycopyrrolate (3) · Tiotropium (2) · Indacaterol-glycopyrronium combination (2) · Budesonide (1) · Formoterol (1) · Batefenterol (1)
Studies
Open first, then newest update. How each study uses GSK573719 is read from its arms, and is right about nine times in ten.
Testing it · 51
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsRecruitingPhase 4University of Tennessee Graduate School of MedicineNCT07133880Written as umeclidinium 62.5 µg and vilanterol 25 µg
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaRecruitingPhase 3GlaxoSmithKlineNCT05757102Written as FF/UMEC/VI
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of ExacerbationRecruitingPhase 4Western University, CanadaNCT07192016Written as fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg
- Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass ExposureRecruitingPhase 4National Institute of Respiratory Diseases, MexicoNCT06571942Written as Vilanterol / Umeclidinium (25/62.5 mcg)
- Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDSuspendedNot applicableMedical University of BialystokNCT07541378Written as Umeclidinium
- Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart FailureCompletedPhase 4Luis Puente MaestuNCT04522596Written as Umeclidinium/vilanterol
- Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover StudyCompletedPhase 4Thammasat UniversityNCT06905483Written as Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPDCompletedPhase 4GlaxoSmithKlineNCT05535972Written as FF/UMEC/VI
- Evaluation of Triple Therapy Using Magnetic Resonance Imaging in AsthmaActive, not recruitingPhase 3Dr. Grace ParragaNCT04651777Written as FF/UMEC/VI
- Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaCompletedPhase 3GlaxoSmithKlineNCT04937387Written as FF/UMEC/VI
- A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT04923347Written as FF/UMEC/VI
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03474081Written as FF/UMEC/VI
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03478696Written as FF/UMEC/VI
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With AsthmaCompletedPhase 2GlaxoSmithKlineNCT03012061Written as UMEC
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4GlaxoSmithKlineNCT03478683Written as FF/UMEC/VI
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignCompletedPhase 4GlaxoSmithKlineNCT03467425Written as FF/UMEC/VI
- Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness StudyWithdrawnPhase 4GlaxoSmithKlineNCT03949842Written as Fluticasone furoate/umeclidinium/vilanterol
- Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT02570165Written as Umeclidinium/ Vilanterol
- Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT02729051Written as FF/UMEC/VI
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled AsthmaWithdrawnPhase 3GlaxoSmithKlineNCT03376932Written as FF/UMEC/VI
See all 51 studies that test GSK573719 →
Given in every arm · 2 — GSK573719 is usual care beside what is tested
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study ACompletedPhase 3GlaxoSmithKlineNCT01328444Written as GSK 573719 125
- Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2GlaxoSmithKlineNCT00515502Written as GSK573719
As the comparator · 1 — what is tested is compared with GSK573719
Codes
What other systems call GSK573719 · ClinicalTrials.gg INT006107
- RxNorm 1487514One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 1487514 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.